Endocrine Abstracts

Background: Adamantinomatous craniopharyngiomas (ACPs) are rare, benign, epithelial tumours of the sellar-suprasellar region. Craniopharyngiomas cause considerable morbidity and mortality due to local invasion and treatment-related damage to surrounding structures, including the hypothalamus and pituitary gland, leading to hypopituitarism and diabetes insipidus (DI). Trametinib is a highly selective mitogen-activated protein kinase (MEK) inhibitor, which has been recently used...

Background: The main aim of growth hormone(GH) treatment during childhood is to attain optimal final height. As a young adult GH treatment is important to achieve optimal body composition (including peak bone mass), psychosocial development and to reduce metabolic and cardiovascular risks. At completion of linear growth (height velocity [HV] <2 cm/year), it is recommended that GH treatment should be discontinued, and GH status reassessed to determine the e...

Introduction: In children, BRAF (e.g. dabrafenib) and MEK (e.g. trametinib) inhibitors are used to treat a range of tumours including low-grade gliomas, Langerhans cell histiocytosis (LCH), and plexiform neurofibromas. However, the ubiquitous nature of the BRAF/MAPK/MEK pathway in various physiological processes means that these treatments are not without their own side effects such as renal tubulopathies (causing hyponatraemia) and hyperglycaemia.Aim: T...